News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022
News Conference News VIVA 2019 IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB L.A. McKeown November 05, 2019
News Conference News VIVA 2017 Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD L.A. McKeown September 18, 2017
News Conference News VIVA 2017 EVAR Outcomes Equivalent Between Men and Women, Registries Show L.A. McKeown September 14, 2017
News Conference News VIVA 2017 DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease L.A. McKeown September 13, 2017
News Conference News VIVA 2016 Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option L.A. McKeown October 12, 2016
News Conference News VIVA 2016 Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear L.A. McKeown September 21, 2016